Original articleGene reprogramming in exercise-induced cardiac hypertrophy in swine: A transcriptional genomics approach
Introduction
Cardiac hypertrophy and remodeling is the response of the heart to an increased workload, stress or injury, in an attempt to maintain or increase cardiac output [1], [2]. Pathological hypertrophy as it occurs in hypertension, valvular diseases or after myocardial infarction (MI), is an independent risk factor for the later development of heart failure [3], [4]. In contrast, physiological hypertrophy such as that occurring during normal growth, pregnancy, or after prolonged exercise-training, is not associated with an increased risk for cardiovascular disease [5], [6]. Exercise-induced hypertrophy is not associated with increased fibrosis and apoptosis, and decreased capillary density, as is seen in various forms of pathological hypertrophy [7]. Physiological hypertrophy and pathological hypertrophy therefore have different cellular and molecular phenotypes which are thought to result from different genetic reprogramming [7], [8], [9].
The majority of studies into the molecular mechanisms underlying physiological hypertrophy have employed rodents subjected to treadmill running, voluntary wheel running or swim training. Various models of physiological hypertrophy in rodents have identified an important role for growth factors such as insulin-like growth factor (IGF-1), and phosphatidylinositol-3-kinase/Akt signaling [10]. Gene expression profiling has shown that expression of cell survival and fatty acid oxidation genes is altered after physiological hypertrophy, whereas genes involved in apoptosis and inflammation were mainly affected in pathological hypertrophy [8], [11], [12], [13]. However, there are significant differences in cardiac physiology between rodents and large laboratory animals [14], [15], such as swine, which in many aspects mimics human cardiac physiology and hemodynamics more closely than rodents [14]. Thus, similar to humans, prolonged exercise-training in swine produces cardiac hypertrophy [16], [17], increases coronary blood flow capacity [18], increases stroke volume [17], and decreases heart rate [16]. However, compared to murine models, studies in large animals into the molecular mechanisms of physiological hypertrophy, and the differences with pathological hypertrophy are scarce.
We hypothesized that LV hypertrophy results from genetic reprogramming through a limited number of transcription factors. We have previously reported on the changes in gene expression profiles, and implicated transcription factors, that underlie hypertrophy of the left ventricle (LV) during recovery from a MI [19]. Here, we studied the molecular pathways that underlie physiological hypertrophy and the TFs that drive these changes in LV hypertrophy caused by 3–6 weeks of dynamic exercise-training in swine. Using the changes in gene expression profiles, we explored the differentially expressed genes for common transcription factor binding sites (TFBSs), and combined these data with protein/DNA array analysis of protein extracts prepared from LV nuclei.
Section snippets
Experimental animals
Studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996) and with approval of the Erasmus University Medical Center Animal Care Committee. Cardiac tissue was collected from 2 to 3 months old pre-pubescent female and neutered male Yorkshire × Landrace swine.
Swine underwent a 3–6 week long (average 31 days, range 18–42 days) incremental dynamic exercise protocol (EX, n = 11). Swine ran 5 days/week on a treadmill starting at 3
Anatomical and hemodynamical data
In swine that were exercise-trained for 3–6 weeks physiological hypertrophy was observed. A 16% increase (P = 0.03) in LV weight to body weight ratio was observed compared with sedentary animals (SED), indicative of LV hypertrophy (Fig. 1A). This was accompanied by a trend towards a lower basal heart rate (− 12%; P = 0.083; Table 1). Cardiac dimensions, as determined by echocardiography in subsets of animals, tended to be higher in EX than SED animals, but this did not reach statistical significance (
Discussion
The present study is the first to investigate the changes in cardiac gene expression during physiological hypertrophy of the left ventricle in a large animal model in an unbiased and integrative fashion. In the present study a protocol of 3–6 weeks of EX in pre-pubescent female and neutered male pigs resulted in a 16% increase in LV weight to body weight ratio and a 35% increase in stroke volume index, whereas heart rate showed a trend towards lower values. To identify TFs that potentially drive
Conclusions
By using an unbiased approach, we identified changes in gene expression and the TFs that are likely involved in the genetic reprogramming that underlies physiological LV hypertrophy in a large animal model. By comparing these genes to previously published gene expression and TF activity data on pathological hypertrophy, a number of genes and TFs were identified that are differentially regulated in both forms of hypertrophy, e.g. PAX6 and GR. These proteins might be at the base of the
Disclosures
None.
Acknowledgments
This work was supported by a grant of the Netherlands Heart Foundation (NHS2005B234).
References (42)
- et al.
Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies
Pharmacol Ther
(Oct 2010) - et al.
Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy
J Biol Chem
(Jun 13 2003) - et al.
TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation
J Mol Cell Cardiol
(Oct 2005) - et al.
Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction
Am J Pathol
(Aug 2001) - et al.
Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF
Gene
(Dec 8 2004) - et al.
Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome
Cell
(Feb 23 1996) - et al.
Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter
J Biol Chem
(Aug 15 2003) - et al.
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior
Cell
(Jul 29 2005) The “modern” view of heart failure: how did we get here?
Circ Heart Fail
(May 2008)- et al.
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy
Circulation
(Jun 27 2000)
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
N Engl J Med
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction
Circulation
Exercise training in coronary artery disease and coronary vasomotion
Circulation
The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death
Circulation
Pathological and physiological hypertrophies are regulated by distinct gene programs
Eur J Cardiovasc Prev Rehabil
Cardiac hypertrophy: the good, the bad, and the ugly
Annu Rev Physiol
Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy
Proc Natl Acad Sci U S A
Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure
BMC Physiol
Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats
Physiol Genomics
Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy
FEBS J
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice
Circ Heart Fail
Cited by (11)
Paired box 6 inhibits cardiac fibroblast differentiation
2020, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Consequently, CF differentiation is an important target for preventing cardiac fibrosis; however, the molecular mechanisms underlying CF differentiation have not yet been fully elucidated. A previous study suggested that the DNA-binding activity of the transcription factor paired box 6 (Pax6) is oppositely regulated in models of exercise-induced hypertrophy and post-myocardial infarction-induced hypertrophy [4]. Thus, Pax6 may play a role in the pathological process of hypertrophy and may participate in the regulation of CF differentiation during cardiac fibrosis.
Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction
2019, Journal of Molecular and Cellular CardiologyCitation Excerpt :There is evidence that Yy1 overexpression is strongly linked with the pathophysiology of adverse cardiac remodeling. In 2014, Kuster and co-workers reported an increase in Yy1 in the remodeled LV of swine post-MI [12]. Using an experimental heart failure model and human heart failure samples, Sucharov and co-workers showed that Yy1 is upregulated in the damaged tissue and acts as a negative regulator of αMyHC gene expression, leading to cardiac hypertrophy [13].
Exercise makes the difference: Deconstructing physiological hypertrophy in swine
2015, Journal of Molecular and Cellular CardiologyCorticosteroid Receptors in Cardiac Health and Disease
2022, Advances in Experimental Medicine and BiologyPAX6 inhibits angiotensin II-induced cardiac fibroblast transdifferentia⁃ tion
2021, Chinese Journal of Pathophysiology
- 1
Present address: Department of Physiology, VU University Medical Center, Amsterdam, The Netherlands.